Immuneering Corp Files Q1 2025 10-Q
Ticker: IMRX · Form: 10-Q · Filed: May 5, 2025 · CIK: 1790340
| Field | Detail |
|---|---|
| Company | Immuneering Corp (IMRX) |
| Form Type | 10-Q |
| Filed Date | May 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
Related Tickers: IMRX
TL;DR
**IMRX Q1 2025 10-Q FILED: Financials updated, check balance sheet details.**
AI Summary
Immuneering Corp filed its 10-Q for the period ending March 31, 2025. The company, located at 245 Main Street, Cambridge, MA, reported on its financial status. Key financial data points include common stock and additional paid-in capital figures for the periods ending March 31, 2025, and December 31, 2024.
Why It Matters
This filing provides investors with an update on Immuneering Corp's financial health and position as of the end of the first quarter of 2025.
Risk Assessment
Risk Level: low — This is a routine financial filing (10-Q) that provides standard financial reporting and does not indicate any unusual risks.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Financial data is as of this date.)
- 2024-12-31 — Prior Period End Date (Comparative financial data is from this date.)
Key Players & Entities
- Immuneering Corp (company) — Filer of the 10-Q
- 245 Main Street, Second Floor, Cambridge, MA 02142 (location) — Company Business Address
- March 31, 2025 (date) — End of Reporting Period
- December 31, 2024 (date) — Prior Period End Date
FAQ
What is the total amount of common stock outstanding as of March 31, 2025?
The filing indicates figures for us-gaap:CommonStockMember and us-gaap:CommonClassAMember and us-gaap:CommonClassBMember for 2025-03-31, but specific dollar amounts are not detailed in this header.
What was Immuneering Corp's net income for the first quarter of 2025?
The provided header information does not contain specific net income figures for the quarter ending March 31, 2025.
What is the company's cash and cash equivalents balance as of March 31, 2025?
Specific line items for cash and cash equivalents are not detailed in the provided header information for the period ending March 31, 2025.
Did Immuneering Corp issue any new shares during the first quarter of 2025?
The filing mentions changes in common stock and additional paid-in capital for the period 2025-01-01 to 2025-03-31, suggesting potential share activity, but specific details are not in the header.
What is the company's total assets as of March 31, 2025?
The header information for the 10-Q filing does not provide the total asset value as of March 31, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 5, 2025 regarding Immuneering Corp (IMRX).